Swissmedic vs EU NB QMS Audits
Overview
Understanding who audits what — and when — is important for efficient QMS management. For Swiss medical devices, QMS oversight comes from two sources: EU-designated notified bodies (as part of Annex IX conformity assessment) and Swissmedic (as part of market surveillance). These are distinct processes with different triggers and scope.
EU NB QMS Audits
Purpose: Formal conformity assessment under MedDO Annex IX Chapter I — establishing that the manufacturer's QMS meets all applicable requirements for the certified device class.
Who conducts: EU-designated NB with scope covering the device class (verified on NANDO).
When triggered: Required for Class IIa, IIb, III and IVD List A/B/Self-test conformity assessment. Initial audit before certificate issuance; annual surveillance audits thereafter; unannounced audit at least once per 5-year certificate period.
What is assessed:
- Full ISO 13485 QMS implementation and effectiveness
- MedDO-specific QMS requirements (UDI, PMS integration, PSUR processes, SSCP for applicable devices)
- Design controls (for Class IIb and III)
- Technical documentation for sampled devices (Chapter II assessment for Class III/IVD List A)
Outcome: NB QMS certificate (typically 5-year validity), annual surveillance audit reports, certificate suspension/withdrawal if major nonconformities found.
Swissmedic QMS Oversight
Purpose: Market surveillance — verifying that devices on the Swiss market continue to comply with MedDO/IVDO requirements.
Who conducts: Swissmedic inspectors.
When triggered: Not on a fixed schedule. Triggered by: market surveillance plans; complaint investigations; vigilance reports indicating potential systemic QMS failures; random inspection programmes; post-FSCA effectiveness verification.
What is assessed: Swissmedic market surveillance inspections typically focus on compliance with specific MedDO obligations rather than full ISO 13485 audit: DAPI registration accuracy; labelling compliance; complaint handling and vigilance reporting processes; FSCA implementation; PMS system operation.
Outcome: Inspection report; compliance assessment; potential enforcement action for non-compliance.
Key Differences Summary
| Aspect | EU NB Annex IX Audit | Swissmedic Market Surveillance |
|---|---|---|
| Basis | Mandatory for conformity assessment | Risk-based / complaint-triggered |
| Frequency | Annual surveillance + initial | Variable, not fixed |
| Scope | Full ISO 13485 + MedDO-specific | Focused on MedDO compliance areas |
| Outcome | QMS certificate / conformity decision | Compliance report / enforcement action |
| Announcement | Generally announced; unannounced ≥1x per 5 years | Can be unannounced |
| Right to refuse | No — manufacturer must cooperate | No — manufacturer must cooperate |
Official Sources
AI-assisted navigation aid only. Always verify against official Swissmedic and Fedlex sources. Not legal or regulatory advice.